Browse SLC2A1

Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein. Melanosome. Note=Localizes primarily at the cell surface. Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
Domain PF00083 Sugar (and other) transporter
Function

Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses.

> Gene Ontology
 
Biological Process GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0005984 disaccharide metabolic process
GO:0005988 lactose metabolic process
GO:0005989 lactose biosynthetic process
GO:0006766 vitamin metabolic process
GO:0006767 water-soluble vitamin metabolic process
GO:0006820 anion transport
GO:0006970 response to osmotic stress
GO:0008643 carbohydrate transport
GO:0008645 hexose transport
GO:0009267 cellular response to starvation
GO:0009306 protein secretion
GO:0009311 oligosaccharide metabolic process
GO:0009312 oligosaccharide biosynthetic process
GO:0009914 hormone transport
GO:0009991 response to extracellular stimulus
GO:0010817 regulation of hormone levels
GO:0015711 organic anion transport
GO:0015749 monosaccharide transport
GO:0015758 glucose transport
GO:0015833 peptide transport
GO:0016051 carbohydrate biosynthetic process
GO:0019852 L-ascorbic acid metabolic process
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0034219 carbohydrate transmembrane transport
GO:0034637 cellular carbohydrate biosynthetic process
GO:0035428 hexose transmembrane transport
GO:0042149 cellular response to glucose starvation
GO:0042594 response to starvation
GO:0042886 amide transport
GO:0042908 xenobiotic transport
GO:0044262 cellular carbohydrate metabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0046351 disaccharide biosynthetic process
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0050708 regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0051180 vitamin transport
GO:0070837 dehydroascorbic acid transport
GO:0071496 cellular response to external stimulus
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:1904659 glucose transmembrane transport
Molecular Function GO:0005355 glucose transmembrane transporter activity
GO:0015144 carbohydrate transmembrane transporter activity
GO:0015145 monosaccharide transmembrane transporter activity
GO:0015149 hexose transmembrane transporter activity
GO:0033300 dehydroascorbic acid transporter activity
GO:0042910 xenobiotic transporter activity
GO:0043621 protein self-association
GO:0051119 sugar transmembrane transporter activity
GO:0051183 vitamin transporter activity
GO:0055056 D-glucose transmembrane transporter activity
GO:1901476 carbohydrate transporter activity
Cellular Component GO:0001939 female pronucleus
GO:0005901 caveola
GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0030496 midbody
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0042470 melanosome
GO:0044448 cell cortex part
GO:0044853 plasma membrane raft
GO:0045120 pronucleus
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0048770 pigment granule
GO:0072562 blood microparticle
GO:0098589 membrane region
GO:0098857 membrane microdomain
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04066 HIF-1 signaling pathway
hsa04911 Insulin secretion
hsa04919 Thyroid hormone signaling pathway
hsa04920 Adipocytokine signaling pathway
hsa04922 Glucagon signaling pathway
hsa04976 Bile secretion
Reactome R-HSA-428790: Facilitative Na+-independent glucose transporters
R-HSA-70153: Glucose transport
R-HSA-189200: Hexose transport
R-HSA-163685: Integration of energy metabolism
R-HSA-5653890: Lactose synthesis
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-422356: Regulation of insulin secretion
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425366: Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
R-HSA-196836: Vitamin C (ascorbate) metabolism
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC2A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC2A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.61; FDR: 0.02000 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC2A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4740.345
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6140.781
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3610.808
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0270.959
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4220.865
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5930.851
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.6230.286
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5990.742
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.480.789
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.50.794
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5010.87
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1380.485
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC2A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC2A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC2A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC2A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC2A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC2A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC2A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC2A1
Namesolute carrier family 2 (facilitated glucose transporter), member 1
Aliases DYT18; DYT9; GLUT1; GLUT; HTLVR; CSE; human T-cell leukemia virus (I and II) receptor; choreoathetosis/spast ......
Chromosomal Location1p34.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC2A1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting SLC2A1.
ID Name Drug Type Targets #Targets
DB02709ResveratrolSmall MoleculeAHR, AKT1, ALOX15, ALOX5, APP, CBR1, CLEC14A, CSNK2A1, ESR1, ITGA5 ......25